Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Reika Yamauchi, Takanori Ito, Sachiyo Yoshio, Takafumi Yamamoto, Kazuyuki Mizuno, Masatoshi Ishigami, Hiroki Kawashima, Satoshi Yasuda, Shigeo Shimose, Hideki Iwamoto, Taiji Yamazoe, Taizo Mori, Eiji Kakazu, Takumi Kawaguchi, Hidenori Toyoda, Tatsuya Kanto
Topics & Concepts
MedicineOsteopontinInternal medicineHepatocellular carcinomaGastroenterologyBevacizumabVascular endothelial growth factorOncologyAtezolizumabCancerPembrolizumabImmunotherapyChemotherapyVEGF receptorsBone and Dental Protein StudiesCancer Research and TreatmentsBone health and treatments